Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

JAGX

Jaguar Health Inc

Jul 26 • 04:00PM ET

1.28

Dollar change -0.07
Percentage change -5.19	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VXF DFAC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-74.86	Insider Own	12.63%	Shs Outstand	4.79M	Perf Week	-69.95%
Market Cap	6.13M	Forward P/E	-	EPS next Y	-2.51	Insider Trans	0.00%	Shs Float	4.18M	Perf Month	-66.84%
Income	-38.32M	PEG	-	EPS next Q	-1.20	Inst Own	1.99%	Short Float	6.83%	Perf Quarter	-87.45%
Sales	10.14M	P/S	0.60	EPS this Y	99.36%	Inst Trans	-58.62%	Short Ratio	0.26	Perf Half Y	-81.45%
Book/sh	2.63	P/B	0.49	EPS next Y	-265.77%	ROA	-68.24%	Short Interest	0.29M	Perf Year	-96.60%
Cash/sh	2.44	P/C	0.53	EPS next 5Y	40.00%	ROE	-351.06%	52W Range	1.26 - 39.60	Perf YTD	-85.91%
Dividend Est.	-	P/FCF	-	EPS past 5Y	86.10%	ROI	-103.37%	52W High	-96.77%	Beta	0.96
Dividend TTM	-	Quick Ratio	1.39	Sales past 5Y	39.38%	Gross Margin	58.02%	52W Low	1.59%	ATR (14)	0.54
Dividend Ex-Date	-	Current Ratio	1.89	EPS Y/Y TTM	94.68%	Oper. Margin	-318.44%	RSI (14)	21.13	Volatility	25.13% 11.29%
Employees	49	Debt/Eq	2.31	Sales Y/Y TTM	-10.29%	Profit Margin	-377.95%	Recom	1.00	Target Price	14.50
Option/Short	No / Yes	LT Debt/Eq	1.56	EPS Q/Q	97.57%	Payout	-	Rel Volume	0.83	Prev Close	1.35
Sales Surprise	-21.63%	EPS Surprise	-100.00%	Sales Q/Q	19.22%	Earnings	May 14 BMO	Avg Volume	1.09M	Price	1.28
SMA20	-63.91%	SMA50	-74.80%	SMA200	-86.77%	Trades		Volume	910,848	Change	-5.19%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-07-21	Initiated	Cantor Fitzgerald	Overweight	$5
Jul-11-17	Initiated	Rodman & Renshaw	Buy	$2

Jul-23-24 12:13PM	Jaguar Health shares slump following Phase III Mytesi failure (Clinical Trials Arena) -58.78%
08:00AM	Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer (ACCESSWIRE)
Jul-18-24 10:30AM	Jaguar Health to Report Phase 3 OnTarget Trial Results for Its Cancer Supportive Care Drug Crofelemer on July 23rd and Hold Investor Webcast that Morning (ACCESSWIRE)
Jun-26-24 08:30AM	Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement (ACCESSWIRE)
Jun-21-24 04:15PM	Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders (ACCESSWIRE)
08:30AM	Loading…
Jun-12-24 08:30AM	Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024 (ACCESSWIRE)
Jun-07-24 04:15PM	Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (ACCESSWIRE) -5.25% +9.42%
May-29-24 08:30AM	Jaguar Health Executes Out-License Deal with Joint Venture Magdalena Biosciences for Botanical Drug Candidate for Schizophrenia (ACCESSWIRE) +8.19%
May-28-24 08:30AM	Investigator-Initiated Trial of Jaguar Health's Crofelemer Yields Positive Results for Functional Diarrhea (ACCESSWIRE) -12.96%
May-23-24 08:30AM	Jaguar Health to Initiate Commercial Footprint in Cancer Supportive Care at American Society of Clinical Oncology (ASCO) Annual Meeting with Exhibit Booth for FDA-Approved Gelclair Oral Mucositis Product (ACCESSWIRE) -33.26%
May-20-24 10:25AM	Red Lobster Bankruptcy: What Happened to the Popular Seafood Chain? (InvestorPlace) -34.78%
09:37AM	Why Is Jaguar Health (JAGX) Stock Down 40% Today? (InvestorPlace)
07:36AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
May-17-24 04:49PM	Jaguar Health Plans 1-for-60 Reverse Split Next Week (MT Newswires) -9.84%
04:15PM	Jaguar Health, Inc. Announces Reverse Stock Split (ACCESSWIRE)
03:02AM	Loading…
May-15-24 03:02AM	Jaguar Health Inc (JAGX) Q1 2024 Earnings Call Transcript Highlights: Strategic Expansions and ... (GuruFocus.com) -7.20%
May-14-24 10:52AM	JAGX Stock Earnings: Jaguar Health Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) -5.30%
08:00AM	Jaguar Health Reports First Quarter 2024 Financial Results (ACCESSWIRE)
May-13-24 12:35PM	REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates (ACCESSWIRE)
May-09-24 10:35AM	Jaguar Health Announces Submission of Clinical Trial Applications for Crofelemer for the Rare Disease Indications Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome (SBS) in Europe (ACCESSWIRE) +15.74%
May-08-24 08:30AM	Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates (ACCESSWIRE) -10.27%
May-07-24 12:31PM	Want $10,000? Invest $1,000 in These 3 Penny Stocks Now (InvestorPlace) -5.99%
May-06-24 09:04AM	Jaguar Health Applies for Investigational New Animal Drug Status for Potential Dog Diarrhea Treatment (MT Newswires)
08:30AM	Crofelemer, Jaguar Healths Prescription Drug Conditionally Approved by the FDA for Chemotherapy-Induced Diarrhea in Dogs, is the Subject of the Companys Investigational New Animal Drug Application for the Indication of General Diarrhea in Dogs (ACCESSWIRE)
May-03-24 07:31AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) +8.46%
Apr-29-24 08:30AM	Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID) (ACCESSWIRE) +15.56%
Apr-22-24 08:45AM	Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company's Expanding Focus on Cancer Supportive Care (ACCESSWIRE) +14.66%
Apr-18-24 08:30AM	Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care (ACCESSWIRE) +7.40%
Apr-16-24 11:34AM	Why Is Jaguar Health (JAGX) Stock Up 44% Today? (InvestorPlace) +50.08%
08:30AM	Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care (ACCESSWIRE)
10:40AM	Loading…
Apr-10-24 10:40AM	What Is Going on With Jaguar Health (JAGX) Stock Today? (InvestorPlace) +28.89%
Apr-09-24 04:15PM	Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders (ACCESSWIRE) +9.76%
Apr-08-24 08:30AM	Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement (ACCESSWIRE)
Apr-02-24 11:24AM	Jaguar Health, Inc. (NASDAQ:JAGX) Q4 2023 Earnings Call Transcript (Insider Monkey)
08:50AM	Jaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International (ACCESSWIRE)
02:22AM	Q4 2023 Jaguar Health Inc Earnings Call (Thomson Reuters StreetEvents)
Apr-01-24 12:52PM	JAGX Stock Earnings: Jaguar Health Misses Revenue for Q4 2023 (InvestorPlace) -14.35%
08:00AM	Jaguar Health Reports 2023 Financial Results (ACCESSWIRE)
Mar-27-24 08:30AM	Jaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updates (ACCESSWIRE) +5.65%
Mar-20-24 08:30AM	GEN to Commercialize Jaguar Health's Crofelemer in Turkey and Eight Neighboring Countries and Invest $2 Million in Jaguar Stock at 75% Premium to Market (ACCESSWIRE) +15.97%
Feb-23-24 08:30AM	Jaguar Health Requests and Receives Hearing on Nasdaq Listing Compliance (ACCESSWIRE) +5.26%
Feb-15-24 08:30AM	Jaguar Health Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs (ACCESSWIRE)
Feb-14-24 08:30AM	Jaguar Health Donates Supply of Mytesi to Humanitarian Aid Organization Direct Relief (ACCESSWIRE)
Feb-12-24 08:30AM	Jaguar Health Announces Submission of Orphan Drug Designation Application to the FDA for Crofelemer for Cholera-Related Diarrhea (ACCESSWIRE) +6.81%
Jan-30-24 08:45AM	Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Study Indicates Psychoactive Activity of Medicinal Plant Utilized for Centuries by Indigenous Peoples in Tropical Regions (ACCESSWIRE) +5.26%
Jan-29-24 08:30AM	Jaguar Health to Present January 31 at The Microcap Conference and Participate in a Fireside Chat February 1 at the Lytham Partners Investor Select Conference (ACCESSWIRE) -7.19%
Jan-25-24 08:30AM	Dog Study Published in PLOS ONE Shows Statistically Significant Results for Use of Jaguar Health's Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea (CTD) (ACCESSWIRE) +11.98%
Jan-05-24 04:15PM	Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (ACCESSWIRE) -6.42% -7.57%
Jan-04-24 08:30AM	Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs) (ACCESSWIRE) +5.06%
Dec-24-23 05:48PM	11 Popular Penny Stocks on Robinhood (Insider Monkey)
Dec-11-23 08:30AM	A Majority of Subjects in Jaguar Health's Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Stage II (ACCESSWIRE) -30.94%
Dec-07-23 08:30AM	MASCC (Multinational Association of Supportive Care in Cancer) Webinar on GI Toxicities from Cancer Therapies Made Possible by Grant From Napo Pharmaceuticals, a Jaguar Health Family Company (ACCESSWIRE) -10.16%
Dec-06-23 08:30AM	Study Data on Quality of Life for Breast Cancer Patients and Survivors, Supported by Napo Pharmaceuticals (a Jaguar Health Family Company), Published on San Antonio Breast Cancer Symposium (SABCS) Website (ACCESSWIRE)
Dec-04-23 08:30AM	FDA Approves Renewal of Canalevia-CA1, Jaguar Healths Drug for Chemotherapy-Induced Diarrhea in Dogs (ACCESSWIRE) +9.55%
Nov-30-23 08:30AM	Jaguar Health to Present December 5 at the MedInvest Oncology Investor Conference (ACCESSWIRE)
Nov-21-23 08:30AM	Top Line Data for Jaguar Healths Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Forthcoming (ACCESSWIRE) -24.81%
Nov-15-23 01:14PM	Jaguar Health, Inc. (NASDAQ:JAGX) Q3 2023 Earnings Call Transcript (Insider Monkey) +15.14%
Nov-14-23 09:00PM	FILAMENT HEALTH ANNOUNCES THIRD QUARTER 2023 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS (PR Newswire) +6.94%
08:00AM	Jaguar Health Reports Third Quarter 2023 Financial Results (ACCESSWIRE)
Nov-10-23 04:15PM	Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (ACCESSWIRE) +6.16%
Nov-09-23 08:30AM	Breast Cancer Related Results of Groundbreaking Napo Pharmaceuticals (a Jaguar Health Family Company) Supported Study on Quality of Life for Cancer Patients and Survivors Accepted for Presentation at the December 2023 San Antonio Breast Cancer Symposium (ACCESSWIRE)
Nov-08-23 10:25AM	Jaguar Health Receives Additional 180-day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule (ACCESSWIRE) +11.28%
08:30AM	Jaguar Health to Hold Investor Webcast Tuesday, November 14th at 8:30 AM Eastern Regarding Q3 2023 Financials & Corporate Updates (ACCESSWIRE)
Nov-07-23 08:30AM	REMINDER: Jaguar Health to Host Virtual Educational Webinar on Rare Intestinal Failure Diseases with Leading Gastroenterologists and Nutrition Experts November 8th from 1:00 PM to 2:30 PM EST (ACCESSWIRE)
Nov-02-23 08:30AM	Jaguar Health Enters Exclusive Crofelemer Revenue Sharing License and Commercialization Agreement with Quadri Pharmaceuticals Store for Rare Intestinal Failure Diseases in Middle East Markets (ACCESSWIRE) -7.91%
Nov-01-23 08:30AM	Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS) (ACCESSWIRE)
07:00AM	Presenting on the Emerging Growth Conference 64 Day 2 on November 2 Register Now (GlobeNewswire)
Oct-31-23 07:00AM	Presenting on the Emerging Growth Conference 64 Day 1 on November 1 Register Now (GlobeNewswire)
Oct-30-23 08:30AM	Magdalena Biosciences, a Joint Venture between Jaguar Health and Filament Health, Receives Second Tranche of Funding from One Small Planet (ACCESSWIRE)
Oct-26-23 08:30AM	Jaguar Health to Present November 1st at Emerging Growth Conference (ACCESSWIRE)
Oct-25-23 08:00AM	Napo Pharmaceuticals, a Jaguar Health Family Company, Accepted to Present Results of Its Pivotal Phase 3 OnTarget Study for Preventive Treatment of Cancer Therapy-Related Diarrhea December 7th at the San Antonio Breast Cancer Symposium (ACCESSWIRE) -8.75%
Oct-23-23 08:30AM	Magdalena Biosciences Initiates Preclinical Study to Evaluate Plant Extracts to Treat Depression, Anxiety, ADHD and Other Mental Health Indications (ACCESSWIRE)
Oct-19-23 08:30AM	Independent Study Conducted at Boston Children's Hospital, Harvard Medical School, Shows Potential Utility of Jaguar Health's Crofelemer for Treatment of MVID, a Rare Childhood Disease (ACCESSWIRE)
Oct-18-23 08:30AM	Napo Pharmaceuticals to Exhibit at the October 25-28 Annual Association of Nurses in AIDS Care (ANAC) Conference for Mytesi, the Companys FDA-Approved Prescription Drug (ACCESSWIRE)
Oct-12-23 08:30AM	Jaguar Health to Present October 17 at the Lytham Partners Fall 2023 Investor Conference and October 18 at the BIO Investor Forum (ACCESSWIRE) +46.28%
Oct-10-23 08:30AM	Jaguar Animal Health Exhibiting at October 12-14 VCS Annual Conference for Canalevia-CA1, the Company's FDA Conditionally Approved Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs (ACCESSWIRE)
Sep-28-23 08:30AM	Jaguar Health to Present October 3 at LD Micro's Main Event Investor Conference, and on October 5 at the Global Capital Network Investor Conference (ACCESSWIRE)
Sep-27-23 08:30AM	Jaguar Health Launches TikTok and Instagram Contest to Raise Awareness About Common Yet Barely Addressed Health Condition: Surprise Diarrhea (ACCESSWIRE)
Sep-26-23 08:30AM	Napo Pharmaceuticals Supports Groundbreaking Study on Quality of Life for Cancer Patients and Survivors (ACCESSWIRE)
Sep-21-23 07:30AM	Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating ADHD (ACCESSWIRE)
07:30AM	FILAMENT HEALTH AND JAGUAR HEALTH JOINT VENTURE MAGDALENA BIOSCIENCES COMPLETES IMPORT OF COCA LEAF FROM PERU (PR Newswire)
Sep-14-23 08:30AM	Jaguar Health Shares Presentation Replay Link from September 11-13, 2023 H.C. Wainwright Annual Global Investment Conference (ACCESSWIRE)
Sep-13-23 08:30AM	Patent Issued in Japan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS) (ACCESSWIRE) -7.05%
Sep-12-23 08:30AM	Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to National Institute of Allergy and Infectious Diseases for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea (ACCESSWIRE)
Sep-11-23 08:30AM	Jaguar Health Shares Replay Link for September 7, 2023 Presentation at Emerging Growth Conference (ACCESSWIRE)
Sep-07-23 08:30AM	Jaguar Health's Executive VP Dr. Karen Brunke Joins BIO's Rare Disease and Orphan Drugs Committee (ACCESSWIRE) -7.22%
Sep-05-23 07:00AM	Presenting on the Emerging Growth Conference on September 6 and 7 Register Now (GlobeNewswire)
Aug-30-23 08:30AM	The Science Times Publishes Article About Jaguar Health's Focus on Developing Crofelemer for Two Rare Disease Indications (ACCESSWIRE)
Aug-28-23 08:30AM	Jaguar Health to Present September 7 at Emerging Growth Conference and at the September 11-13 H.C. Wainwright Annual Global Investment Conference (ACCESSWIRE)
Aug-24-23 07:00AM	Jaguar Health Engages B2i Digital to Deploy Cutting-Edge Investor Engagement Campaign (ACCESSWIRE) -6.19%
Aug-17-23 08:30AM	Napo Pharmaceuticals, a Jaguar Health Family Company, Reports Completion of Last Patient Last Visit for its Pivotal Phase 3 OnTarget Trial of Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea (ACCESSWIRE)
Aug-16-23 08:30AM	Napo Pharmaceuticals Surveys of Neurologists, Patients, and Caregivers Regarding Amyotrophic Lateral Sclerosis (ALS) Treatment Indicate Real World Burden of Diarrhea and Potential Treatment Interruption (ACCESSWIRE)
Aug-14-23 10:16PM	Q2 2023 Jaguar Health Inc Earnings Call (Thomson Reuters StreetEvents) -6.47%
08:00AM	Jaguar Health Reports Second Quarter 2023 Financial Results (ACCESSWIRE)
Aug-10-23 08:30AM	Jaguar Health to Hold Investor Webcast Monday, August 14th at 8:30 AM EDT Regarding Q2 2023 Financials & Corporate Updates (ACCESSWIRE) +8.12%
Aug-09-23 08:30AM	Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to BARDA for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea (ACCESSWIRE) -10.16%
Aug-08-23 08:30AM	Napo Pharmaceuticals, a Jaguar Health Company, Announces Activation by FDA of Investigational New Drug (IND) Application for Crofelemer for Treatment of Microvillus Inclusion Disease (ACCESSWIRE)
07:00AM	Presenting on the Emerging Growth Conference on August 9 & 10 Register Now (GlobeNewswire)
Aug-07-23 08:30AM	Independent Study Published in Clinical Breast Cancer Shows Activity of Jaguar Health's Crofelemer for Neratinib-induced Diarrhea (ACCESSWIRE)
Aug-03-23 08:30AM	Jaguar Health to Present Aug 4th at Wall Street Wonders Investment Group Luncheon in NYC (ACCESSWIRE) -5.23%

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the Human Health and Animal Health segments. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment includes commercializing prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

JAGX

Jaguar Health Inc

Upgrade your FINVIZ experience